| abstract |
Described herein are methods and compositions for treating prostate cancer in a subject in need thereof. Prostate cancer is castration resistant and may be an androgen receptor antagonist resistant prostate cancer. The method can include administering to the subject a CYP17 lyase inhibitor of formula II. In some cases, the subject has undergone castration, such as chemical castration or surgical castration, or treatment to reduce androgen receptor antagonist treatment or nascent androgen production, such as interference with the steroidogenesis pathway, such as CYP- Receiving 17 lyase inhibitor or receiving combination therapy. |